Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report)'s stock price reached a new 52-week low during trading on Tuesday. The company traded as low as $26.23 and last traded at $26.7450, with a volume of 1,213 shares traded. The stock had previously closed at $26.97.
Analyst Ratings Changes
A number of research analysts have commented on VERA shares. Cantor Fitzgerald restated an "overweight" rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. HC Wainwright dropped their target price on Vera Therapeutics from $90.00 to $75.00 and set a "buy" rating for the company in a report on Friday, November 6th. TD Cowen restated a "buy" rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Raymond James Financial set a $87.00 price target on Vera Therapeutics in a research note on Friday, November 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $74.93.
View Our Latest Stock Analysis on Vera Therapeutics
Vera Therapeutics Trading Down 1.9%
The business's fifty day simple moving average is $30.93 and its 200 day simple moving average is $36.15. The company has a current ratio of 7.91, a quick ratio of 10.92 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.91 billion, a P/E ratio of -4.49 and a beta of 1.07.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, topping analysts' consensus estimates of ($1.62) by $0.32. The company had revenue of $10.28 million during the quarter, compared to the consensus estimate of $3.42 million. As a group, analysts expect that Vera Therapeutics, Inc. will post -6.00 EPS for the current year.
Insider Activity
In other news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the completion of the sale, the chief executive officer owned 235,244 shares in the company, valued at $8,704,028. The trade was a 7.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company's stock.
Hedge Funds Weigh In On Vera Therapeutics
Several large investors have recently bought and sold shares of the business. Allworth Financial LP raised its position in shares of Vera Therapeutics by 66.3% during the 3rd quarter. Allworth Financial LP now owns 1,515 shares of the company's stock valued at $49,000 after acquiring an additional 604 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new position in shares of Vera Therapeutics in the 3rd quarter worth $32,000. Steward Partners Investment Advisory LLC grew its stake in shares of Vera Therapeutics by 110.4% during the third quarter. Steward Partners Investment Advisory LLC now owns 2,045 shares of the company's stock worth $66,000 after purchasing an additional 1,073 shares during the period. Arizona State Retirement System grew its stake in shares of Vera Therapeutics by 12.3% during the second quarter. Arizona State Retirement System now owns 11,813 shares of the company's stock worth $507,000 after purchasing an additional 1,295 shares during the period. Finally, ADAR1 Capital Management LLC increased its holdings in Vera Therapeutics by 8.8% in the first quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company's stock valued at $645,000 after purchasing an additional 1,300 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.
Vera Therapeutics Company Profile
(
Get Free Report)
Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.
While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.